Prot# COL13: Pilot Phase II Study of Safety & Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered with Chemotherapy, Alone or in Combination with Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients w/ Metastatic Colorectal Adenocarcinoma

Project: Research project

StatusFinished
Effective start/end date2/18/031/1/11

Funding

  • Aventis Pasteur Inc. (COL13)